Compare Unichem Lab with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB PROCTER & GAMBLE HEALTH UNICHEM LAB/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 61.3 52.7 116.5% View Chart
P/BV x 0.7 4.8 13.8% View Chart
Dividend Yield % 2.1 10.0 21.1%  

Financials

 UNICHEM LAB   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    UNICHEM LAB
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
UNICHEM LAB/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs2923,549 8.2%   
Low Rs1821,301 14.0%   
Sales per share (Unadj.) Rs167.7511.4 32.8%  
Earnings per share (Unadj.) Rs-3.661.3 -5.9%  
Cash flow per share (Unadj.) Rs5.974.0 8.0%  
Dividends per share (Unadj.) Rs4.00440.00 0.9%  
Dividend yield (eoy) %1.718.1 9.3%  
Book value per share (Unadj.) Rs372.3927.8 40.1%  
Shares outstanding (eoy) m70.3816.60 424.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.44.7 29.8%   
Avg P/E ratio x-65.339.6 -165.0%  
P/CF ratio (eoy) x39.932.8 121.7%  
Price / Book Value ratio x0.62.6 24.4%  
Dividend payout %-110.2717.9 -15.3%   
Avg Mkt Cap Rs m16,68040,257 41.4%   
No. of employees `0002.61.1 229.5%   
Total wages/salary Rs m2,3931,313 182.3%   
Avg. sales/employee Rs Th4,535.27,486.7 60.6%   
Avg. wages/employee Rs Th919.81,157.6 79.5%   
Avg. net profit/employee Rs Th-98.2897.2 -10.9%   
INCOME DATA
Net Sales Rs m11,8018,490 139.0%  
Other income Rs m984244 403.5%   
Total revenues Rs m12,7858,734 146.4%   
Gross profit Rs m-8351,482 -56.4%  
Depreciation Rs m674211 319.0%   
Interest Rs m750-   
Profit before tax Rs m-6001,514 -39.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m-343563 -61.1%   
Profit after tax Rs m-2561,017 -25.1%  
Gross profit margin %-7.117.5 -40.5%  
Effective tax rate %57.337.1 154.2%   
Net profit margin %-2.212.0 -18.1%  
BALANCE SHEET DATA
Current assets Rs m20,38415,343 132.9%   
Current liabilities Rs m5,0291,960 256.6%   
Net working cap to sales %130.1157.6 82.5%  
Current ratio x4.17.8 51.8%  
Inventory Days Days10549 215.0%  
Debtors Days Days13528 474.1%  
Net fixed assets Rs m9,0231,209 746.2%   
Share capital Rs m141166 84.8%   
"Free" reserves Rs m26,05815,235 171.0%   
Net worth Rs m26,19915,401 170.1%   
Long term debt Rs m00-   
Total assets Rs m31,49617,595 179.0%  
Interest coverage x-7.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 77.6%   
Return on assets %-0.65.8 -9.9%  
Return on equity %-1.06.6 -14.8%  
Return on capital %-2.010.3 -19.5%  
Exports to sales %69.40-   
Imports to sales %00-   
Exports (fob) Rs m8,188NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m8,1881,636 500.4%   
Fx outflow Rs m5964,368 13.6%   
Net fx Rs m7,592-2,732 -277.9%   
CASH FLOW
From Operations Rs m-3,278-1,304 251.4%  
From Investments Rs m-2,86012,697 -22.5%  
From Financial Activity Rs m-24-301 8.1%  
Net Cashflow Rs m-4,69011,093 -42.3%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 15.1 18.2 83.0%  
FIIs % 3.0 1.0 300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 29.1 108.9%  
Shareholders   20,176 28,591 70.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  ALEMBIC LTD  

Compare UNICHEM LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Oct 18, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS